NASDAQ:PTCT

PTC Therapeutics Stock Forecast, Price & News

$44.64
+0.42 (+0.95 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.32
$44.86
50-Day Range
$37.95
$48.59
52-Week Range
$37.12
$70.82
Volume834,691 shs
Average Volume559,635 shs
Market Capitalization$3.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.01
30 days | 90 days | 365 days | Advanced Chart
Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


PTC Therapeutics logo

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

606th out of 2,100 stocks

Pharmaceutical Preparations Industry

294th out of 831 stocks

Analyst Opinion: 4.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

Is PTC Therapeutics a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTC Therapeutics stock.
View analyst ratings for PTC Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than PTC Therapeutics?

Wall Street analysts have given PTC Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PTC Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for PTC Therapeutics
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings data on Tuesday, May, 4th. The biopharmaceutical company reported ($1.83) earnings per share for the quarter, missing analysts' consensus estimates of ($1.59) by $0.24. The biopharmaceutical company had revenue of $117.94 million for the quarter, compared to analyst estimates of $98.77 million. PTC Therapeutics had a negative net margin of 105.50% and a negative trailing twelve-month return on equity of 95.96%. The business's revenue for the quarter was up 72.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.81) earnings per share.
View PTC Therapeutics' earnings history
.

How has PTC Therapeutics' stock price been impacted by COVID-19?

PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PTCT stock has decreased by 5.2% and is now trading at $44.64.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PTCT?

14 brokerages have issued twelve-month price targets for PTC Therapeutics' stock. Their forecasts range from $47.00 to $86.00. On average, they expect PTC Therapeutics' stock price to reach $65.08 in the next twelve months. This suggests a possible upside of 45.8% from the stock's current price.
View analysts' price targets for PTC Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the following people:
  • Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 61, Pay $1.7M)
  • Dr. Allan Steven Jacobson, Independent Co-Founder, Chairman of Scientific Advisory Board & Director (Age 75, Pay $140k)
  • Ms. Emily Luisa Hill, Chief Financial Officer (Age 40, Pay $782.5k)
  • Dr. Neil Almstead, Chief Technical Operations Officer (Age 54, Pay $797.41k)
  • Mr. Mark Elliott Boulding, Exec. VP & Chief Legal Officer (Age 60, Pay $804.35k)
  • Mr. Eric Pauwels, Chief Bus. Officer (Age 59, Pay $975.14k)
  • Ms. Christine Utter, Sr. VP, Chief Accounting Officer & Head of People Services (Age 43)
  • Ms. Ellen Welch Ph.D., Chief Scientific Officer
  • Alex Kane, Investor Relations Officer
  • Ms. Jane Baj, VP of Corp. Communications

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics CEO Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among PTC Therapeutics' employees.

Who are some of PTC Therapeutics' key competitors?

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.81%), Franklin Resources Inc. (7.78%), RTW Investments LP (7.51%), Janus Henderson Group PLC (4.36%), Price T Rowe Associates Inc. MD (3.06%) and Alliancebernstein L.P. (2.44%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends for PTC Therapeutics
.

Which institutional investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Panagora Asset Management Inc., Goldman Sachs Group Inc., Bamco Inc. NY, UBS Asset Management Americas Inc., Third Security LLC, Sectoral Asset Management Inc, and Franklin Resources Inc.. Company insiders that have sold PTC Therapeutics company stock in the last year include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey, and Stuart Walter Peltz.
View insider buying and selling activity for PTC Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying PTC Therapeutics stock?

PTCT stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Armistice Capital LLC, Renaissance Technologies LLC, BlackRock Inc., Woodline Partners LP, Millennium Management LLC, Geode Capital Management LLC, and Janus Henderson Group PLC.
View insider buying and selling activity for PTC Therapeutics
or or view top insider-buying stocks.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $44.64.

How much money does PTC Therapeutics make?

PTC Therapeutics has a market capitalization of $3.15 billion and generates $380.77 million in revenue each year. The biopharmaceutical company earns $-438,160,000.00 in net income (profit) each year or ($6.50) on an earnings per share basis.

How many employees does PTC Therapeutics have?

PTC Therapeutics employs 959 workers across the globe.

What is PTC Therapeutics' official website?

The official website for PTC Therapeutics is www.ptcbio.com.

Where are PTC Therapeutics' headquarters?

PTC Therapeutics is headquartered at 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.